GET DAILY SIGNALSKamada (KMDA) Reports Q3 Revenue Growth and Raises Full-Year Guidance
Key Takeaways
- Kamada reported third-quarter 2026 revenue of $52.03 million, up 11% from $47.01 million a year earlier.
- Nine-month revenue reached a record $152.2 million, an increase of approximately 12% year over year.
- Diluted earnings per share (EPS) of $0.14 beat the consensus estimate of $0.13, while revenue came in slightly below the $52.76 million estimate.
- Third-quarter net income climbed 51% to $8.0 million, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 30% to $15.2 million.
- Management raised full-year 2026 guidance and projected continued double-digit revenue and profit growth in 2027.
Why These Results Matter for Kamada
Kamada is a global biopharmaceutical company focused on specialty plasma-derived therapies and a portfolio of products for rare and serious conditions. Its third-quarter report matters because it offers investors a read on demand for lead products such as KEDRAB, an anti-rabies immunoglobulin, alongside VARIZIG and HEPAGAM B. The company has delivered a string of double-digit revenue gains as U.S. utilization expands, and this quarter tests whether that momentum can continue while margins improve. The results also carry weight for the company's broader strategy of expanding plasma collection and building its biosimilar distribution business, both of which are expected to shape long-term profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Numbers
Kamada reported third-quarter 2026 revenue of $52.03 million, up 11% from $47.01 million a year ago, while nine-month revenue reached a record $152.2 million, a roughly 12% increase. Diluted EPS came in at $0.14, up from $0.09 a year earlier and slightly ahead of the $0.13 consensus estimate; revenue, however, was modestly below the $52.76 million analysts had projected.
Net income for the quarter was $8.0 million, up 51% year over year, with adjusted EBITDA of $15.2 million, up 30% and representing a 29% margin. Gross profit was $23.3 million, with a gross margin of 45%. For the nine-month period, net income totaled $21.4 million, or $0.37 per diluted share, up 29%, while adjusted EBITDA rose 20% to $40.9 million. Operating cash flow for the first nine months reached $37.6 million, up from $17.9 million a year earlier, and cash and short-term investments stood at $75.3 million at quarter-end.
Management raised full-year 2026 guidance to revenue of $205 million to $208 million and adjusted EBITDA of $52 million to $54 million, from a prior range of $200 million to $205 million and $50 million to $53 million. The company also declared a $0.14 per-share dividend, bringing total 2026 dividends to roughly $32.3 million.
Market Reaction and Investor Sentiment
The third-quarter print was broadly positive but mixed relative to expectations. A beat on EPS alongside record nine-month sales and raised guidance supported the growth narrative, while the slight revenue miss against consensus and a modestly lower nine-month gross margin of 43% (versus 44% a year earlier) gave investors points to scrutinize. Sentiment heading into the report had been shaped by expanding U.S. demand for KEDRAB, which management says holds at least 50% market share, and by early-stage progress in plasma collection and biosimilars. The dividend declaration and the projection of double-digit growth in 2027 reinforced confidence in the company's cash generation and commercial momentum.
Forward Outlook and Key Factors to Monitor
Kamada's raised 2026 guidance signals management's confidence that current demand trends will continue. Investors will be watching whether KEDRAB utilization in the U.S. keeps rising above distributor Kedrion's minimum commitment, particularly given the company's stated inventory and manufacturing capacity to support further growth.
Plasma collection represents another area of focus. Normal source plasma sales are expected to begin in the fourth quarter of 2026 under a three-year agreement, but the financial benefit of vertical integration is still developing. Because collected plasma must pass through validation before contributing to profitability, the timing and scale of that contribution will be a key factor in the quarters ahead.
The distribution segment, which grew 35% to $24.1 million in the first nine months, is also worth monitoring. New biosimilar launches in Israel and expansion into the Middle East and North Africa (MENA) region provide additional growth avenues. Management has guided for biosimilar revenue of roughly $10 million in 2028 and $20 million to $25 million by 2030.
Finally, mergers and acquisitions (M&A) remain central to the company's four-pillar strategy. Management has indicated that opportunities are in hand, and any completed transaction could accelerate growth beyond the current organic trajectory. Cost discipline and gross-margin trends will also be watched closely as operating expenses rise to support expanded commercial operations. From what I see, the combination of organic growth and potential M&A keeps the setup interesting for the longer term.
Using Tickeron’s AI Tools in My Research
I often turn to Tickeron’s AI Screener when reviewing earnings releases like this one. It helps me quickly filter stocks by fundamentals, technical patterns, and industry trends so I can compare names such as KMDA against peers without spending hours on manual work. The platform has become a regular part of how I organize ideas before digging deeper into specific reports.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KMDA's Stochastic Oscillator is sitting in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KMDA's RSI Indicator exited the oversold zone, 12 of 17 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
Following a +3.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where KMDA advanced for three days, in 174 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
KMDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KMDA as a result. In 69 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 68%.
The Moving Average Convergence Divergence Histogram (MACD) for KMDA turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 33 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.
KMDA moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for KMDA crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KMDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
The Aroon Indicator for KMDA entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.548) is normal, around the industry mean (7.271). P/E Ratio (19.026) is within average values for comparable stocks, (0.479). Projected Growth (PEG Ratio) (0.644) is also within normal values, averaging (2.202). Dividend Yield (0.094) settles around the average of (0.061) among similar stocks. P/S Ratio (2.487) is also within normal values, averaging (181.047).
The Tickeron Seasonality Score of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 48 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. KMDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in pharmaceutical business
Industry PharmaceuticalsGeneric
Advertisement